Sionna Therapeutics, Inc. (NASDAQ:SION) Given Average Recommendation of “Moderate Buy” by Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has earned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $53.2222.

A number of research analysts have issued reports on SION shares. JonesTrading upped their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus upped their price objective on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Finally, Citizens Jmp restated a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a research report on Tuesday, May 26th.

Sionna Therapeutics Trading Up 2.8%

Shares of NASDAQ SION traded up $1.23 during trading on Tuesday, reaching $44.34. The company had a trading volume of 151,727 shares, compared to its average volume of 361,396. Sionna Therapeutics has a twelve month low of $16.38 and a twelve month high of $48.44. The stock has a 50-day moving average price of $39.85 and a two-hundred day moving average price of $39.51. The stock has a market capitalization of $2.00 billion, a PE ratio of -22.98 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, sell-side analysts predict that Sionna Therapeutics will post -2.57 EPS for the current year.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Peter A. Thompson sold 235,863 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This represents a 6.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the sale, the director owned 3,247,025 shares in the company, valued at $144,947,196. This trade represents a 6.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,949,650 shares of company stock worth $88,113,693. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SION. Russell Investments Group Ltd. purchased a new position in shares of Sionna Therapeutics during the 3rd quarter worth about $30,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics in the second quarter valued at approximately $31,000. GF Fund Management CO. LTD. purchased a new stake in Sionna Therapeutics in the fourth quarter valued at approximately $36,000. Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.